Joel Isaacson & Co. LLC Raises Stock Holdings in Novo Nordisk A/S $NVO

Joel Isaacson & Co. LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 2.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,884 shares of the company’s stock after acquiring an additional 571 shares during the quarter. Joel Isaacson & Co. LLC’s holdings in Novo Nordisk A/S were worth $1,441,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. North Capital Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter worth about $27,000. Copeland Capital Management LLC boosted its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after buying an additional 255 shares during the period. Stone House Investment Management LLC purchased a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $30,000. Disciplina Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY purchased a new position in Novo Nordisk A/S during the 1st quarter worth $35,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NVO. HSBC set a $70.00 price objective on Novo Nordisk A/S in a report on Wednesday, October 1st. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Morgan Stanley cut shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and lowered their price target for the stock from $59.00 to $47.00 in a research report on Monday, September 29th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective on the stock in a report on Wednesday, August 13th. Finally, Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $77.50.

View Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Price Performance

Shares of NVO opened at $59.67 on Tuesday. The company has a 50 day moving average of $54.73 and a two-hundred day moving average of $63.51. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $120.56. The company has a market cap of $266.43 billion, a price-to-earnings ratio of 16.39, a price-to-earnings-growth ratio of 2.63 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.